Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Mercadal Santiago,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,Genevray Magali,Zharkov Artem,Dixon Mark,Brewster Michael,Barrett Martin,MacDonald David (2017) Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial, LANCET HAEMATOLOGY, vol. 4, br. 6, str. E272-E282 (Article) 

Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Phillippe,Barrett Martin,Berge Claude,Bittner Beate,Boehnke Axel,McIntyre Christine,MacDonald David (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study, LANCET ONCOLOGY, vol. 15, br. 3, str. 343-352 (Article) 

Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,McIntyre Christine,Barrett Martin,Macdonald David (2013) Subcutaneous Rituximab and Chemotherapy Achieves Similar Trough Levels, Safety, and Response as Intravenous Rituximab in First-Line Follicular Lymphoma: Stage 1 Results of the Phase 3 Sabrina Study, HAEMATOLOGICA, vol. 98, br. , str. 131-132 (Meeting Abstract)